Altered gut microbiota in patients with small intestinal bacterial overgrowth.
clinical intestinal disorders
intestinal disorders
small bowel
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
06
06
2022
received:
14
03
2022
accepted:
26
09
2022
pubmed:
1
10
2022
medline:
18
1
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
Small intestinal bacterial overgrowth (SIBO) is diagnosed by using quantitative culture of duodenal aspirates and/or a hydrogen breath test. However, few studies have analyzed bacterial microbiota in Japanese patients with SIBO. Twenty-four patients with any abdominal symptoms and suspected SIBO were enrolled. Quantitative culture of duodenal aspirates and a glucose hydrogen breath test were performed on the same day. SIBO was diagnosed based on a bacterial count ≥ 10 Small intestinal bacterial overgrowth was diagnosed in 17 of the 24 patients (71%). The positive rates for the hydrogen breath test and quantitative culture of duodenal aspirates were 50% and 62%, respectively. Patients with SIBO showed significantly reduced α-diversity compared with non-SIBO patients, and analysis of β-diversity revealed significantly different distributions between SIBO and non-SIBO patients. In addition, the intestinal microbiome in SIBO patients was characterized by increased relative abundance of Streptococcus and decreased relative abundance of Bacteroides compared with non-SIBO patients. Duodenal dysbiosis was identified in patients with SIBO and may play a role in the pathophysiology of SIBO.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Small intestinal bacterial overgrowth (SIBO) is diagnosed by using quantitative culture of duodenal aspirates and/or a hydrogen breath test. However, few studies have analyzed bacterial microbiota in Japanese patients with SIBO.
METHODS
METHODS
Twenty-four patients with any abdominal symptoms and suspected SIBO were enrolled. Quantitative culture of duodenal aspirates and a glucose hydrogen breath test were performed on the same day. SIBO was diagnosed based on a bacterial count ≥ 10
RESULTS
RESULTS
Small intestinal bacterial overgrowth was diagnosed in 17 of the 24 patients (71%). The positive rates for the hydrogen breath test and quantitative culture of duodenal aspirates were 50% and 62%, respectively. Patients with SIBO showed significantly reduced α-diversity compared with non-SIBO patients, and analysis of β-diversity revealed significantly different distributions between SIBO and non-SIBO patients. In addition, the intestinal microbiome in SIBO patients was characterized by increased relative abundance of Streptococcus and decreased relative abundance of Bacteroides compared with non-SIBO patients.
CONCLUSIONS
CONCLUSIONS
Duodenal dysbiosis was identified in patients with SIBO and may play a role in the pathophysiology of SIBO.
Substances chimiques
RNA, Ribosomal, 16S
0
Hydrogen
7YNJ3PO35Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Subventions
Organisme : ASKA Pharmaceutical Co., Ltd.
Organisme : Japan Agency for Medical Research and Development
ID : JP20gm1010008h9904
Organisme : Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 18K08002
Organisme : Health and Labor Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan
ID : 20FC1037
Informations de copyright
© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594.
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J. Gastroenterol. 2018; 53: 807-818.
Kumar K, Ghoshal UC, Srivastava D, Misra A, Mohindra S. Small intestinal bacterial overgrowth is common both among patients with alcoholic and idiopathic chronic pancreatitis. Pancreatology 2014; 14: 280-283.
Bauer TM, Steinbruckner B, Brinkmann FE et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am. J. Gastroenterol. 2001; 96: 2962-2967.
Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211.
Sung HJ, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients. J. Neurogastroenterol. Motil. 2015; 21: 545-551.
Lauritano EC, Bilotta AL, Gabrielli M et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J. Clin. Endocrinol. Metab. 2007; 92: 4180-4184.
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am. J. Gastroenterol. 2020; 115: 165-178.
Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am. J. Gastroenterol. 2017; 112: 775-784.
Bouhnik Y, Alain S, Attar A et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am. J. Gastroenterol. 1999; 94: 1327-1331.
Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. Cell. Microbiol. 2011; 13: 670-676.
Kirsch M. Bacterial overgrowth. Am. J. Gastroenterol. 1990; 85: 231-237.
Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology 1998; 45: 1643-1650.
Leite G, Morales W, Weitsman S et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS ONE 2020; 15: e0234906.
Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand. J. Gastroenterol. 1993; 28: 681-687.
Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of Bacteria and Archaea using next-generation sequencing. PLoS ONE 2014; 9: e105592.
Hisada T, Endoh K, Kuriki K. Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese. Arch. Microbiol. 2015; 197: 919-934.
Aronesty E. Comparison of sequencing utility programs. Open Bioinforma J. 2013; 7: 1-8.
Bolyen E, Rideout JR, Dillon MR et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019; 37: 852-857.
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 2016; 13: 581-583.
DeSantis TZ, Hugenholtz P, Larsen N et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 2006; 72: 5069-5072.
Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat. Protoc. 2020; 15: 799-821.
Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 2017; 45: W180-W188.
Segata N, Izard J, Waldron L et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12: R60.
Saffouri GB, Shields-Cutler RR, Chen J et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 2019; 10: 2012.
Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 2013; 37: 1103-1111.
Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 2018; 9: 2247.
Imai T, Inoue R, Kawada Y et al. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 2019; 54: 149-159.
Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin. Gastroenterol. Hepatol. 2013; 11: 483-490.